The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Access · International · continued

Availability by country, dated, with primary sources posts 31–60

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

JC
j.castellanosTL2 Moderator23 Oct 2025#31
k.bettencourt, post #22: On post #18 — agreed on the reasoning, with one qualification. Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear. Go to post

I read post #29 twice before replying, because I had assumed the opposite.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

5 likes in reply to #22 9mo
JS
j.sorensenTL2 Moderator24 Oct 2025#32
Knowlton, post #16: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

0 likes in reply to #16 9mo
LC
lu.cabreraTL2 Moderator25 Oct 2025#33

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

0 likes 9mo
VS
v.salgadoTL2 Moderator26 Oct 2025 · edited#34

post #33 is right about the mechanism and I think understates the practical bit.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

19 likes 9mo
C
chromatogramTL4Analytical chemist27 Oct 2025#35

Coming back to post #33, because the follow-up matters more than the original answer.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

8 likes 9mo
EK
e.kuuselaTL2 Moderator27 Oct 2025#36
e.kimani, post #15: Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks. Go to post

Picking up post #33: that is the part I would want checked first.

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

2 likes in reply to #15 9mo
JM
j.mwangiTL4 Moderator28 Oct 2025#37

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

0 likes 9mo
CR
c.ramosTL2 Moderator29 Oct 2025#38

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

27 likes 9mo
P
preregisteredTL330 Oct 2025#39
JV
j.vogelTL2 Moderator31 Oct 2025#40

This follows post #37 rather than contradicting it.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

0 likes 9mo
K
KnowltonTL3Regular31 Oct 2025#41

Picking up post #38: that is the part I would want checked first.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

8 likes 9mo
JH
j.hartmannTL2 Moderator1 Nov 2025 · edited#42

Coming back to post #40, because the follow-up matters more than the original answer.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

19 likes 9mo
V
VThorvaldsenTL3Regular2 Nov 2025#43

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

0 likes 9mo
SA
s.achebeTL2 Moderator3 Nov 2025#44
e.ferrari, post #17: Coming back to post #15, because the follow-up matters more than the original answer. Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing… Go to post

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

2 likes in reply to #17 9mo
PA
p.amankwahTL2 Moderator3 Nov 2025#45
j.sorensen, post #32: Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent. Go to post

This follows post #42 rather than contradicting it.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

4 likes in reply to #32 9mo
NR
n.rahimiTL24 Nov 2025#46
DP
d.petrescuTL2 Moderator5 Nov 2025#47

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

0 likes 9mo
IC
i.coelhoTL2 Moderator6 Nov 2025#48

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

0 likes 9mo
FK
f.kimaniTL2 Moderator6 Nov 2025#49
r.oyelaran, post #19: Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory. Go to post

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

2 likes in reply to #19 9mo
K
KLindqvistTL4 Moderator7 Nov 2025#50
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

8 likes 9mo
MV
m.vukovicTL2 Moderator8 Nov 2025#51
Lundqvist, post #24: Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had been repeating something I had not checked carefully enough. Go to post

On post #47 — agreed on the reasoning, with one qualification.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

17 likes in reply to #24 9mo
NG
np_gilmoreTL3Nurse practitioner9 Nov 2025#52
i.broberg, post #13: Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. Go to post

post #51 answers the question as asked. The question underneath it is different.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

7 likes in reply to #13 9mo
RZ
ro.zielinskiTL2 Moderator9 Nov 2025 · edited#53

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

0 likes 9mo
SC
sourced_claimsTL3Regular10 Nov 2025#54

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

33 likes 9mo
RS
r.serranoTL2 Moderator11 Nov 2025#55
k.farrugia, post #20: post #19 is right about the mechanism and I think understates the practical bit. Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary. Go to post

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

23 likes in reply to #20 9mo
OB
owen.bradyTL4 Moderator12 Nov 2025#56
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

post #55 is right about the mechanism and I think understates the practical bit.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

11 likes 8mo
JE
j.erdoganTL2 Moderator12 Nov 2025#57

I read post #55 twice before replying, because I had assumed the opposite.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

1 like 8mo
PP
peak_purityTL3Analytical chemist13 Nov 2025#58

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

0 likes 8mo
JI
j.ivaturiTL2 Moderator14 Nov 2025#59
j.vogel, post #40: This follows post #37 rather than contradicting it. Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. Go to post

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

7 likes in reply to #40 8mo
RH
revision_historyTL3Wiki editor14 Nov 2025#60

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

1 like 8mo